Objective:To explore the efficacy and adverse reactions of sacituzumab govitecan (SG) in the posterior-line therapy for advanced malignant tumors.Methods:A retrospective case series study was conducted. The clinicopathological data of 20 patients with advanced malignant tumors who were treated with SG after multiple lines of treatment in Nanjing BenQ Hospital From July to December 2023 were retrospectively analyzed. The short-term efficacy and treatment-related adverse events (TRAE) were evaluated.Results:Among the 20 patients, there were 7 males and 13 females, the median age [ M ( Q1, Q3)] was 60.0 (53.8, 72.5) years old, the median line of previous anti-tumor regimens was 4.5 (3.3, 6.0) lines, and the median duration time of SG treatment was 52.5 (35.8, 72.5) days. After SG treatment, there were 3 cases (15.0%) with partial response, including breast cancer, vaginal squamous cell carcinoma and endometrial carcinoma, 10 cases (50.0%) with stable disease and 7 cases (35.0%) with progressive disease. The objective response rate was 15.0% (3/20), and the disease control rate was 65.0% (13/20). Two cases (10.0%) were discontinued due to intolerable adverse reactions. The incidence of TRAE was 75.0% (15/20), of which the incidence of ≥grade 3 TRAE was 10.0% (2/20), including neutropenic fever and ventricular arrhythmia. Conclusions:SG has a certain therapeutic effect and controllable safety in the posterior-line therapy for advanced malignant tumors.

Objective:To explore the efficacy and adverse reactions of sacituzumab govitecan (SG) in the posterior-line therapy for advanced malignant tumors.Methods:A retrospective case series study was conducted. The clinicopathological data of 20 patients with advanced malignant tumors who were treated with SG after multiple lines of treatment in Nanjing BenQ Hospital From July to December 2023 were retrospectively analyzed. The short-term efficacy and treatment-related adverse events (TRAE) were evaluated.Results:Among the 20 patients, there were 7 males and 13 females, the median age [ M ( Q1, Q3)] was 60.0 (53.8, 72.5) years old, the median line of previous anti-tumor regimens was 4.5 (3.3, 6.0) lines, and the median duration time of SG treatment was 52.5 (35.8, 72.5) days. After SG treatment, there were 3 cases (15.0%) with partial response, including breast cancer, vaginal squamous cell carcinoma and endometrial carcinoma, 10 cases (50.0%) with stable disease and 7 cases (35.0%) with progressive disease. The objective response rate was 15.0% (3/20), and the disease control rate was 65.0% (13/20). Two cases (10.0%) were discontinued due to intolerable adverse reactions. The incidence of TRAE was 75.0% (15/20), of which the incidence of ≥grade 3 TRAE was 10.0% (2/20), including neutropenic fever and ventricular arrhythmia. Conclusions:SG has a certain therapeutic effect and controllable safety in the posterior-line therapy for advanced malignant tumors.